BidaskClub lowered shares of Portola Pharmaceuticals (NASDAQ:PTLA) from a hold rating to a sell rating in a report released on Wednesday, December 4th, BidAskClub reports.
A number of other research analysts also recently weighed in on PTLA. Cowen reissued a buy rating and set a $45.00 target price on shares of Portola Pharmaceuticals in a research report on Tuesday, November 5th. Goldman Sachs Group started coverage on shares of Portola Pharmaceuticals in a research report on Friday, November 8th. They set a neutral rating and a $35.00 target price for the company. Morgan Stanley initiated coverage on shares of Portola Pharmaceuticals in a research report on Thursday, September 5th. They set a hold rating and a $37.00 target price for the company. Zacks Investment Research raised shares of Portola Pharmaceuticals from a hold rating to a buy rating and set a $30.00 price objective for the company in a report on Wednesday, October 9th. Finally, ValuEngine downgraded shares of Portola Pharmaceuticals from a sell rating to a strong sell rating in a report on Monday, October 21st. Two analysts have rated the stock with a sell rating, four have issued a hold rating and five have issued a buy rating to the company. Portola Pharmaceuticals presently has a consensus rating of Hold and a consensus price target of $38.75.
Shares of Portola Pharmaceuticals stock traded down $0.33 on Wednesday, reaching $25.06. 691,800 shares of the company traded hands, compared to its average volume of 847,501. Portola Pharmaceuticals has a 52 week low of $16.08 and a 52 week high of $37.95. The company has a 50 day moving average of $27.54 and a 200 day moving average of $27.77. The firm has a market capitalization of $1.98 billion, a PE ratio of -5.00 and a beta of 2.06. The company has a debt-to-equity ratio of 1.25, a current ratio of 5.88 and a quick ratio of 5.85.
Portola Pharmaceuticals (NASDAQ:PTLA) last released its earnings results on Tuesday, November 5th. The biopharmaceutical company reported ($0.68) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.82) by $0.14. Portola Pharmaceuticals had a negative net margin of 275.13% and a negative return on equity of 282.04%. The firm had revenue of $36.80 million during the quarter, compared to the consensus estimate of $34.64 million. During the same period in the prior year, the firm earned ($1.08) EPS. The company’s revenue was up 159.2% compared to the same quarter last year. As a group, analysts anticipate that Portola Pharmaceuticals will post -3.49 earnings per share for the current year.
In other news, Director Hollings Renton sold 5,000 shares of the firm’s stock in a transaction on Friday, November 1st. The shares were sold at an average price of $30.00, for a total transaction of $150,000.00. Following the sale, the director now owns 18,194 shares in the company, valued at approximately $545,820. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 4.50% of the company’s stock.
Several institutional investors have recently bought and sold shares of PTLA. Los Angeles Capital Management & Equity Research Inc. raised its position in shares of Portola Pharmaceuticals by 45.2% during the 2nd quarter. Los Angeles Capital Management & Equity Research Inc. now owns 18,310 shares of the biopharmaceutical company’s stock valued at $497,000 after buying an additional 5,700 shares in the last quarter. Fisher Asset Management LLC raised its position in shares of Portola Pharmaceuticals by 16.6% during the 2nd quarter. Fisher Asset Management LLC now owns 100,722 shares of the biopharmaceutical company’s stock valued at $2,733,000 after buying an additional 14,338 shares in the last quarter. First Trust Advisors LP purchased a new stake in shares of Portola Pharmaceuticals during the 2nd quarter valued at $3,110,000. Aperio Group LLC purchased a new stake in shares of Portola Pharmaceuticals during the 2nd quarter valued at $152,000. Finally, J. L. Bainbridge & Co. Inc. purchased a new stake in shares of Portola Pharmaceuticals during the 2nd quarter valued at $202,000.
Portola Pharmaceuticals Company Profile
Portola Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes novel therapeutics in the areas of thrombosis and other hematologic disorders and inflammation in the United States. The company offers Andexxa, an antidote for patients treated with rivaroxaban and apixaban when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding; and Bevyxxa (betrixaban), an oral, once-daily Factor Xa inhibitor for the prevention of venous thromboembolism in adult patients hospitalized for an acute medical illness.
Featured Story: Float
Receive News & Ratings for Portola Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Portola Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.
